Immunocore Appoints Travis Coy as CFO

By Bobby Samwell • Thursday, January 02 15:19 • Permanent Link

Immunocore Holdings PLC (NASDAQ: IMCR) has announced the appointment of Travis Coy as the Executive Vice President (EVP), Chief Financial Officer, and Head of Corporate Development, effective January 1, 2025. Coy, who previously served as a non-executive director, brings over 20 years of experience from Eli Lilly and Company, where he held various roles in finance and business development, including his most recent position as Vice President, Head of Transactions and M&A, Corporate Business Development.

Immunocore's CEO, Bahija Jallal, expressed delight at Coy's appointment, highlighting his deep knowledge of the company and its science, which she believes will be invaluable in his new role. Professor Sir John Bell, Chairman of the Board of Immunocore, also commended Coy for his service on the board and expressed anticipation of working with him in his new role as CFO.

Travis Coy expressed excitement about his transition from a board member to leading the finance and corporate development functions at Immunocore. He emphasized his eagerness to collaborate with the executive team to deliver transformative medicines to patients with cancer, infectious diseases, and autoimmune diseases using the company's differentiated platform and strong financial base.

Immunocore, a commercial-stage biotechnology company, is pioneering the development of a novel class of TCR bispecific immunotherapies called Immtax, designed to treat a broad range of diseases, including cancer, autoimmune diseases, and infectious diseases. The company has a deep pipeline with nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. Its most advanced oncology TCR therapeutic, Kimmtrak, has received approval for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries.

Immunocore's press release does not contain any specific financial metrics or performance indicators for the current period. As a result of these announcements, the company's shares have moved 1.3% on the market, and are now trading at a price of $29.89. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.